89 reports of this reaction
3.8% of all CEFPROZIL reports
#1 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #1 most commonly reported adverse reaction for CEFPROZIL, manufactured by Ascend Laboratories, LLC. There are 89 FDA adverse event reports linking CEFPROZIL to CHRONIC KIDNEY DISEASE. This represents approximately 3.8% of all 2,368 adverse event reports for this drug.
Patients taking CEFPROZIL who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among CEFPROZIL users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for CEFPROZIL:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 89 FDA reports for CEFPROZIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 3.8% of all adverse event reports for CEFPROZIL, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking CEFPROZIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.